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Abstract
Background: Elevated post-prandial blood glucose during pregnancy has been associated with adverse pregnancy
and offspring outcomes, such as maternal gestational diabetes and excessive foetal growth. The ROLO Study is a
randomized controlled trial (RCT) investigating the effect of a low glycaemic index (GI) diet in pregnancy to prevent
foetal macrosomia (birth weight > 4000 g). We described the impact of a low-GI diet on the maternal and feto-placental
unit metabolism by studying how the ROLO intervention affected maternal and cord blood metabolomes.
Methods: Fasting maternal plasma samples pre- and post-intervention of 51 pregnant women and 132 cord blood
samples were measured with a targeted metabolomics approach using liquid-chromatography coupled to tandem mass
spectrometry. The differences between RCT groups were explored via multivariate models with covariates correction.
Significance was set at Bonferroni-corrected level of 0.05.
Results: A total of 262 metabolites species, sums and ratios were investigated. While no metabolite reached statistical
significance after Bonferroni correction, many maternal phospholipids and acylcarnitines were elevated in the
intervention group at uncorrected 0.05 alpha level. Most species contained saturated and monounsaturated fatty acid
chains with 16 or 18 carbon atoms. In cord blood, no differences were identified between RCT groups.
Conclusions: A low-GI diet in pregnancy was associated with a trend to modest but consistent changes in maternal
lipid and fatty acid metabolism. The intervention seemed not to affect foetal metabolism. Our exploratory findings may
be used to direct further investigations about low GI diets before and during pregnancy, to improve patient care for
pre-conceptional and pregnant women with lipid dysregulations and potentially modulate the offspring’s risk for future
metabolic diseases.
Trial registration: Current Controlled Trials ISRCTN54392969.
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Background
Pregnancy is a period of major endocrine and metabolic
changes which modulate both maternal and child’s
health [10]. Pregnancy exposures such as gestational dia-
betes mellitus (GDM), elevated maternal pre-pregnancy
body-mass-index (BMI) and gestational weight gain
(GWG) are risk factors for type 2 diabetes, overweight, and
metabolic syndrome not only in the mother [3, 10, 27] but
also in the offspring, as suggested by the numerous indica-
tions for the Developmental Origins of Health and Disease
(DOHaD) hypothesis [12, 24]. Therefore, it is important to
understand the mechanisms driving these changes and to
build the foundation for acting timely to prevent the onset
of disease in mothers and children.
One possible intervention strategy involves targeting
maternal blood glucose levels. Elevated fasting and post-
prandial blood glucose levels, even in absence of overt
pre-existing diabetes or GDM, have been associated with
adverse outcomes for mother and child [33]. Nutritional
and dietary measures to ameliorate glycaemic control
are standard in pregnant women with diabetes and
GDM [21]. One dietary parameter of interest is the gly-
caemic index (GI). The GI of a carbohydrate-containing
food, expressed on a scale from 0 to 100, quantifies the
peak in the blood sugar concentrations after ingestion of
the food [25]; therefore, the consumption of low GI foods
is considered desirable to achieve good glycaemic control.
Several randomized control trials to investigate the ef-
fect of low-GI diet on maternal and new-born outcomes
have been conducted, reporting favourable effects on
maternal glycaemic control but heterogeneous results re-
garding offspring outcomes [48]. In particular, there is a
lack of knowledge regarding how a low-GI diet may im-
pact maternal and feto-placental metabolism at a mo-
lecular level in a real-environment clinical setting. In
this study, we aim to provide insights into this question
using a metabolomics approach. Metabolomics is the
omics branch investigating small (< 1.5 kDa) intermedi-
ates and products of metabolic reactions and is an estab-
lished tool in metabolism research, with potential
applications in precision medicine and personalized pa-
tient care [2, 23, 37]. Ultimately, this exploratory study
could inform clinical practise on treatments for pregnant
women, aimed at increasing maternal wellbeing and de-
creasing the offspring’s risk for future metabolic conditions.
Materials and methods
Study participants and data collection
This was a secondary analysis conducted on data from the
ROLO study. The ROLO study (Randomised cOntrol trial
of LOw glycaemic index diet versus no dietary intervention
to prevent recurrence of foetal macrosomia, 2007–2011,
Dublin, Ireland) tested the hypothesis of a low-GI diet in
pregnant women to reduce birth weight in secundigravida
with a previous macrosomic child (birth weight > 4000 g);
the intervention group (n = 394) received an educational
session about low-GI diet at the beginning of the second
trimester, while the standard group (n = 406) received
standard care only (trial registration: Current Controlled
Trials ISRCTN54392969) [46].
Recruitment and the first study visit took place at the
end of the first pregnancy trimester (median: 13th gesta-
tion week) and rapidly followed by the educational ses-
sion (median: 15th week); additional visits were held at
28th and 34th weeks of gestation.
Maternal age at delivery, early pregnancy weight and
BMI, weight at 34th week, gestational age at delivery,
newborn’s sex, weight and length were documented.
Gestational weight gain (GWG) was defined as weight at
last measured visit (38th or 40th gestational week) after
subtraction of early pregnancy weight; for cases with
missing weight at 38th or 40th week, GWG was imputed
by adding the overall ROLO median GWG between
34th and 38th week to the weight measured at 34th
week. Newborn’s ponderal index at birth was calculated
as 100 ∙ birth weight (g) / birth length3 (cm3).
Maternal fasting blood samples were collected at re-
cruitment and again at the 28th week. Cord blood was
collected at delivery. Total, HDL and LDL cholesterol
were measured via Roche cholesterol oxidase method
and direct HDL Roche 3rd generation method, respect-
ively, on the cobas C702 module of the Roche Cobas
8000 analyser (Roche Diagnostics GmbH, Penzberg,
Germany); the Friedewald equation was used to estimate
LDL-cholesterol concentrations [7].
Three-days food diaries were collected in each preg-
nancy trimester and evaluated by a research dietitian via
WISP software version 3.0 (Tinuviel Software, Llanfechell,
UK) [32]. From these data, the absolute GI intake and the
proportion of energy derived from saturated, monoun-
saturated and polyunsaturated fat intake, expressed as per-
centage of total energy intake (% kcal), were derived.
Metabolomics measurements
For subgroups of evaluable mother/child pairs, aliquots
of the collected samples were provided for metabolomics
analysis. Plasma samples were measured in a targeted
approach using liquid chromatography coupled to tan-
dem mass spectrometry (LC/MS-MS) in the laboratory
of the Division of Metabolic and Nutritional Medicine,
Dr. von Hauner Children’s Hospital (LMU Munich). Five
classes of metabolites were analysed: amino acids (AA),
non-esterified fatty acids (NEFA), acylcarnitines (AC),
branched chain keto acids (BCKA) and intermediates of
TCA cycle (TCA), and phospholipids (PL) (including
sphingomyelins (SM), diacyl-phosphatidylcholines (PCaa),
acyl-alkyl-phosphatidylcholines (PCae) and lysophosphati-
dylcholines (LPC)). After preparation, samples were
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randomly distributed in 4 96-wells batches with maternal
blood (1–4) and 3 batches with cord blood (5–7). In each
batch, up to 80 test samples were measured together with
6 quality control (QC) samples (prepared as pooled mix-
ture of the samples from batch 1, for maternal blood, or
from batch 5, for cord blood) and 10 standards used for
quantification. The injection of the samples was random-
ized in each run, with QC and standards being injected
regularly every 6–7 test samples. Measurements and QC
were performed separately for each blood source.
Samples preparation
Proteins of 50 μL plasma were precipitated on a plate
with PTFE filter elements by adding 450 μL methanol in-
cluding internal standards (ISD). After centrifugation the
filtrate was split into aliquots for the analyses of individ-
ual methods.
Amino acids
Fifty μL of the filtrate was used for the derivatization to
AA butyl ester with hydrochloric acid in 1-butanol ac-
cording to the method described by Harder et al. [15]. A
set of labeled amino acid standards (set A, Cambridge
Isotope Laboratories) mixed with L-Asparagine (15 N2,
98%, Cambridge Isotope Laboratories) and L-Tryptophan
(Indole-D5, 98%, Cambridge Isotope Laboratories) was
used as internal standard (ISD). After evaporation, the
residues were dissolved in water/methanol (80:20) with
0.1% formic acid and determined by LC-MS/MS equipped
with 150 × 2.1mm, 3.5 μm particle size C18 HPLC col-
umn (X-Bridge, Waters, Milford, USA) and 0.1% hepta-
fluorobutyric acid as ion pair reagent in mobile phase A
(water) and B (methanol). MS detection was performed
with a triple quadrupole mass spectrometer (API2000,
Sciex, Darmstadt, Germany) with atmospheric pressure
chemical ionization source (APCI) operating in positive
ion ionization mode.
NEFA
Fifty μL of the filtrate was diluted with100 μL methanol
and injected to a LC-MS/MS operating in negative
electrospray ionization (ESI) mode for identification of
NEFA as described by Hellmuth et al. [16]. Uniformly
13C-labeled palmitic acid was used as ISD. Samples were
injected to an HPLC system (1200, Agilent, Waldbronn,
Germany) with a UPLC diphenyl column (Pursuit UPS
Diphenyl, Agilent, Waldbronn, Germany). Five mM am-
monium acetate and 2.1 mM acetic acid in water were
used as mobile phase A and acetonitrile/isopropanol
(80/20) as mobile phase B. A hybrid triple quadrupole
mass spectrometer (4000 QTRAP, Sciex, Darmstadt,
Germany) operating in negative ESI multiple reaction
monitoring mode (MRM) mode was used for MS detec-
tion. This method allows for the separation of NEFA
species differing in chain length and number of double
bonds, but not in the position of double bonds. The
analytical process was post-processed using Analyst soft-
ware version 1.6.2.
BCKA and TCA
Organic and keto-acids were measured by a modified
method based on previously published procedures [4, 30].
D3-methylmalonic acid (Cambridge Isotope Laboratories,
Teweeksbury, MA, USA) was used as ISD. One hundred
μL of the supernatant were evaporated to dryness and re-
suspended in 50 μL water. Five μL of the extracted
samples were injected by HPLC system (1200, Agilent,
Waldbronn, Germany) on a Kinetex F5 core-shell HPLC
column, 150 × 2.1 mm, 2.6 μm particle size (Kinetex F5,
Phenomenex, Aschaffenburg, Germany) for chromato-
graphic separation of molecular species. The mobile phase
A was water with 1% formic acid and mobile phase B was
composed of methanol/isopropanol (50/50) with 1% for-
mic acid. A gradient elution at a flow rate of 250 μL/min
was held constant for 1min with 1% B, raised to 65% B
within 6min, and turned back to initial conditions of 1%B
within 0.5min. The triple quadrupole mass spectrometer
(4000QTRAP, Sciex, Darmstadt, Germany) was operated
in negative scheduled MRM mode using ESI.
Phospholipids
Phospholipids were analyzed as described by Uhl et al.
[45] using LPC (13:0) and PC (14:0/14:0) (Avanti Polar
Lipids, Alabaster, Alabama, USA) as ISD. Thirty μL of
the centrifuged supernatant were mixed for 20 min
at 600 rpm with 500 μl methanol containing 1.2 mM
ammonium acetate. Phospholipids were analyzed by flow-
injection analysis (FIA) in a triple quadrupole mass
spectrometer (QTRAP4000, Sciex, Darmstadt, Germany)
coupled to a LC system (1200 Agilent, Waldbronn,
Germany). ESI was used in positive ionization mode. MS/
MS analysis was run in positive MRM mode with 184 Da
(choline head group) as product ion for the PL. Analyst
1.6.2 software, followed by in-house processing with the
statistical software R [44], was used for post-processing.
The number of carbon atoms (XX) and double bonds (Y)
is expressed in the form C XX:Y.
Acylcarnitines
D3-carnitine-C2, D3-carnitine-C8 and D3-carnitine-C16
(all Cambridge Isotope Laboratories, Teweeksbury, MA,
USA) were used as ISDs. FIA with isocratic elution with
76% isopropanol, 19% methanol and 5% water was used
to measure acylcarnitines. The mass spectrometer (4000
QTRAP, Sciex, Darmstadt, Germany) was equipped with
ESI and operated in positive ionization mode.
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Quality control
To ensure precision of the measured samples, 6 QC
samples, pooled from the test samples, were measured
in each batch. Batches with a coefficient of variation
(CV) > 25% were excluded. If at least 75% of the batches
for a metabolite passed the intra-batch quality control,
the inter-batch CV was calculated, and the metabolite
was kept if CV < 30%. In each batch, at most one QC
sample was allowed to be an outlier (defined as measure-
ment further away than 1.5 interquartile range (IQR)
from the next measurement) and removed.
After quality control, 6 sums and ratios were addition-
ally calculated: sums of PCaa, PCae, total PC, total SM,
ratio of total SM to total PC, ratios of NEFA 18:1/18:0
and 16:1/16:0 depicting SCD-1 activity [6], and five
ratios of AC 2:0 to mid-chain AC (AC 14:0, 16:0, 16:1,
18:0, 18:1) depicting fatty acid oxidation (FAO) [29].
Statistical treatment
Data preparation
QC and statistical treatment of the data were performed
using the statistical software R version 3.4.3 [44].
To ensure interpretability of the results, only subjects
with covariates information, mothers with longitudinal
metabolomics data (full set analysis) and babies born
after the 37th gestational weeks were included. The final
sample sizes for maternal and cord analyses were thus
51 and 132 subjects, respectively. Metabolomics outliers
identification and removal was performed before models
calculation within each blood source and visit time
point; outliers were defined as concentration values
further away than 3 standard deviations from the next
measurements.
Covariables are presented descriptively as median
(IQR) or as absolute number (percentage), stratified by
blood source and RCT arms. Variables were compared
in the two RCT arms using Mann Whitney U-tests.
Main models
For each metabolite, a generalized additive model (GAM)
was calculated using the function gam() from the R pack-
age mgcv [47]. In the following notations, s(∙) indicates a
non-linear effect and 1|∙ the random intercept.
The models for maternal metabolites were calculated
as follows: metabolite at 28 weeks ~ RCT group + ma-
ternal BMI +metabolite at 13 weeks + s (sample storage
time) + 1|batch number. Full results are presented in
Additional file 1. Maternal age was included in a first
step, but since preliminary results showed weak to no
associations with maternal age, the variable was removed
to preserve statistical power. For some metabolites of
interest, a sensitivity analysis was conducted by re-calcu-
lating the models after trimming the highest and lowest
5 concentration values. Additional univariate and
multivariate sensitivity analyses (including the associ-
ation of selected metabolites with dietary fat intakes)
and their results are presented in Additional file 2.
The models for cord metabolites were calculated as fol-
lows: metabolite ~ RCT group + maternal BMI + gesta-
tional age + foetal sex + s (sample storage time) + 1|batch
number. As sensitivity analysis, the following covariates
were included one at a time in the model: ponderal index
(PI) of the new-born, maternal GWG, cord HDL, LDL
and total cholesterol. Since the results did not substan-
tially change, these are not presented. Additionally, the
calculation of the main model was repeated by including
only those maternal/child dyads for which also maternal
blood was analysed.
Significance and reported values
From these models, the standardized beta estimates, un-
corrected and Bonferroni-corrected p-values and 95%
confidence interval of the beta estimate for the RCT
variable are reported. Associations with Bonferroni-cor-
rected p-values < 0.05 were defined as ‘significant’, asso-
ciations with uncorrected p-values < 0.05 were defined
as ‘trends’. False discovery rate (FDR) p-values correc-
tion was also applied, but, since the significant metabo-
lites did not differ between the two approaches, we used
only Bonferroni due to its easier interpretation. Metabo-
lites with uncorrected RCT p-value < 0.05 were visually
inspected via grouped boxplots. Results of these models
are presented in graphical form via Manhattan plots.
Results
Covariates
The covariates, stratified for the two subpopulations
(maternal blood samples/cord blood samples), are pre-
sented in Table 1. Maternal samples from 51 mothers
(control/intervention: 26/25) and 132 cord blood samples
(68/64) were included in the analysis; both maternal and
cord blood were analysed for 48 mother/child dyads. Only
GI in trimester 2 (i.e. after the intervention) and gestational
age were significantly different between the RCT arms.
Metabolites
Two hundred twenty-nine analytes were used in the ana-
lyses for maternal blood, 197 in cord blood. A total of
257 analytes passed the quality control in at least one of
the blood sources, 170 of which in both. These were:
sum of hexoses (H1), 22 AA, 33 NEFA, 26 AC (including
free carnitine), 8 TCA, 2 BCKA, 7 LPC, 24 PCaa, 26
PCae, and 21 SM. In both blood sources it was addition-
ally possible to investigate sums and ratios.
RCT and maternal blood
After Bonferroni correction, no significant differences
were found (see Fig. 1 and Additional file 1). However,
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Table 1 Demographic and clinical variables of the subjects included in the analyses
Maternal blood Cord blood
Control group
(n = 26)
Intervention group
(n = 25)
p-value Control group
(n = 68)
Intervention group
(n = 64)
p-value
Maternal anthropometry and blood parameters
Maternal BMI (kg/m2) 24.34 ± 4.40 26.36 ± 5.33 [1] NS 25.38 ± 4.27 26.24 ± 4.36 [1] NS
Maternal age (years) 33.37 ± 5.73 32.30 ± 6.89 NS 33.00 ± 5.04 32.45 ± 6.31 NS
Gestational weight gain (kg) 13.20 ± 4.06 [7] 12.18 ± 4.74 [7] NS 13.20 ± 4.59 [13] 12.40 ± 4.69 [16] NS
Fasting glucose, 13th week (mmol/l) 4.50 ± 0.40 [1] 4.40 ± 0.50 NS 4.50 ± 0.40 [4] 4.50 ± 0.40 [2] NS
Fasting glucose, 28th week (mmol/l) 4.60 ± 0.42 [2] 4.50 ± 0.30 NS 4.50 ± 0.60 [3] 4.50 ± 0.50 [2] NS
Total cholesterol, 13th week (mmol/l) 4.77 ± 0.92 [9] 4.81 ± 1.01 [8] NS 4.76 ± 1.06 [28] 5.25 ± 1.32 [25] 0.072
Total cholesterol, 28th week (mmol/l) 6.31 ± 1.30 [8] 6.39 ± 1.06 [9] NS 6.16 ± 1.13 [26] 6.46 ± 1.30 [24] NS
HDL cholesterol, 13th week (mmol/l) 0.80 ± 0.26 [9] 0.93 ± 0.38 [8] NS 0.78 ± 0.28 [28] 0.87 ± 0.40 [25] NS
HDL cholesterol, 28th week (mmol/l) 0.97 ± 0.32 [8] 1.04 ± 0.34 [9] NS 0.93 ± 0.39 [26] 1.02 ± 0.40 [24] NS
LDL cholesterol, 13th week (mmol/l) 3.35 ± 0.64 [9] 3.45 ± 1.03 [8] NS 3.34 ± 0.89 [28] 3.64 ± 0.90 [25] NS
LDL cholesterol, 28th week (mmol/l) 4.71 ± 1.40 [8] 4.62 ± 1.22 [9] NS 4.26 ± 1.33 [26] 4.75 ± 1.23 [24] NS
LDL cholesterol, difference
28th - 13th week (mmol/l)
0.83 ± 1.47 [9] 1.06 ± 0.60 [9] NS 0.98 ± 1.17 [29] 1.01 ± 0.83 [27] NS
Maternal diet
Daily energy intake T1 (kcal) 1803.28 ± 357.75 [4] 1873.09 ± 420.48 [5] NS 1876.03 ± 506.89 [10] 1793.15 ± 467.24 [13] NS
Daily energy intake T2 (kcal) 1839.30 ± 279.74 [4] 1775.72 ± 532.19 [4] NS 1932.25 ± 434.53 [10] 1759.49 ± 534.65 [11] 0.085
Daily energy intake T3 (kcal) 1915.07 ± 334.97 [4] 1800.89 ± 450.74 [3] NS 2022.50 ± 494.67 [10] 1768.26 ± 473.59 [10] 0.027
Daily GI T1 57.10 ± 6.76 [4] 57.09 ± 3.57 [6] NS 57.13 ± 5.45 [11] 56.98 ± 4.38 [14] NS
Daily GI T2 58.52 ± 2.99 [4] 55.25 ± 2.95 [6] 0.004 57.66 ± 3.93 [11] 55.65 ± 3.42 [14] 0.001
Daily GI T3 58.60 ± 3.97 [4] 56.61 ± 3.72 [6] NS 57.76 ± 4.83 [11] 56.15 ± 4.21 [14] NS
Total fat intake T1 (g) 71.35 ± 22.41 [4] 70.32 ± 26.29 [5] NS 76.10 ± 22.08 [10] 72.13 ± 25.26 [13] NS
Saturated fat intake T1 (g) 30.26 ± 11.38 [4] 27.74 ± 11.65 [5] NS 31.12 ± 10.23 [10] 27.35 ± 14.41 [13] 0.057
Monounsaturated fat intake T1 (g) 22.59 ± 7.08 [4] 23.26 ± 6.53 [5] NS 23.81 ± 6.42 [10] 23.91 ± 7.22 [13] NS
Polyunsaturated fat intake T1 (g) 10.87 ± 6.05 [4] 10.73 ± 5.37 [5] NS 10.87 ± 5.65 [10] 10.80 ± 5.11 [13] NS
Total fat intake T2 (g) 71.80 ± 13.20 [4] 70.49 ± 26.74 [4] NS 75.01 ± 24.54 [10] 70.25 ± 25.53 [11] 0.077
Saturated fat intake T2 (g) 26.97 ± 10.95 [4] 24.51 ± 8.20 [4] NS 29.56 ± 10.96 [10] 24.51 ± 11.56 [11] 0.019
Monounsaturated fat intake T2 (g) 21.91 ± 4.80 [4] 22.75 ± 7.53 [4] NS 23.34 ± 8.38 [10] 22.63 ± 8.73 [11] NS
Polyunsaturated fat intake T2 (g) 11.39 ± 5.60 [4] 10.79 ± 6.03 [4] NS 12.23 ± 5.41 [10] 10.55 ± 4.76 [11] NS
Total fat intake T3 (g) 75.28 ± 22.81 [4] 73.48 ± 30.10 [3] NS 79.31 ± 22.91 [10] 70.82 ± 29.12 [10] NS
Saturated fat intake T3 (g) 28.49 ± 10.77 [4] 29.32 ± 18.93 [3] NS 29.92 ± 12.11 [10] 26.37 ± 13.87 [10] NS
Monounsaturated fat intake T3 (g) 23.33 ± 6.30 [4] 24.43 ± 8.99 [3] NS 25.56 ± 7.54 [10] 21.56 ± 10.81 [10] NS
Polyunsaturated fat intake T3 (g) 10.17 ± 5.23 [4] 13.01 ± 5.69 [3] NS 12.04 ± 5.32 [10] 11.34 ± 5.36 [10] NS
Total fat intake T1 (%kcal) 0.37 ± 0.09 [4] 0.34 ± 0.06 [5] NS 0.38 ± 0.07 [10] 0.35 ± 0.08 [13] NS
Saturated fat intake T1 (%kcal) 14.76 ± 5.36 [4] 13.49 ± 4.31 [5] NS 15.16 ± 4.63 [10] 13.55 ± 4.09 [13] NS
Monounsaturated fat intake T1 (%kcal) 11.68 ± 3.59 [4] 11.20 ± 2.93 [5] NS 11.76 ± 3.14 [10] 11.34 ± 3.75 [13] NS
Polyunsaturated fat intake T1 (%kcal) 5.71 ± 2.18 [4] 5.31 ± 1.74 [5] NS 5.64 ± 1.92 [10] 5.09 ± 2.33 [13] NS
Total fat intake T2 (%kcal) 0.36 ± 0.06 [4] 0.36 ± 0.06 [4] NS 0.36 ± 0.07 [10] 0.35 ± 0.06 [11] NS
Saturated fat intake T2 (%kcal) 13.39 ± 3.91 [4] 12.93 ± 4.72 [4] NS 13.60 ± 3.87 [10] 12.56 ± 4.36 [11] NS
Monounsaturated fat intake T2 (%kcal) 11.21 ± 2.81 [4] 10.76 ± 2.78 [4] NS 11.57 ± 2.56 [10] 10.90 ± 3.14 [11] NS
Polyunsaturated fat intake T2 (%kcal) 5.63 ± 1.86 [4] 5.93 ± 1.86 [4] NS 5.57 ± 1.91 [10] 5.48 ± 1.97 [11] NS
Total fat intake T3 (%kcal) 0.36 ± 0.06 [4] 0.36 ± 0.04 [3] NS 0.36 ± 0.06 [10] 0.36 ± 0.06 [10] NS
Saturated fat intake T3 (%kcal) 13.50 ± 4.34 [4] 14.10 ± 4.27 [3] NS 13.73 ± 4.00 [10] 13.24 ± 3.76 [10] NS
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40 metabolites were higher in intervention than control
arm at uncorrected 0.05 level (see Table 2): two NEFA
(16:1 and 18:1), eight mid-chain AC (with chain length
from 8 to 18 carbon atoms), three LPC (with chain
lengths of 16 and 18 carbon atoms), 15 PCaa and PCae
(13 of which containing a 16- or 18-carbon atom
saturated or monounsaturated fatty acid (FA) chain),
and 12 SM (with saturated or monounsaturated FA
chains). The sum of SM and two FAO markers were also
significantly higher (uncorrected 0.05 level) in the inter-
vention group; no other sum or ratio was different
between the groups.
RCT and cord blood
No significant difference was found (see Fig. 2), and
weak trends for elevated values in the intervention group
were identified for only 3 metabolites: NEFA 14:1 and
15:1 and AC 20:0 (see Additional file 1). The subanalysis
including only overlapping mother/child dyads delivered
a similar picture, with PCaa 30:0, AC 4:0 and the
branched-chain AA (BCAA) Valine (Val) showing a
trend for lower values in the intervention group. Val, in
particular, was more strongly different than the other
two analytes (uncorrected p = 0.005). This subpopulation
did not significantly differ in the baseline characteristics
from the total population.
Discussion
In this study, we explored the impact of a dietary inter-
vention promoting a low-GI diet during pregnancy on
the metabolome of pregnant women and cord blood of
their offspring. We found that the low-GI diet was asso-
ciated with consistently higher concentrations of phos-
pholipids (PL) and acylcarnitines (AC) in maternal blood
Table 1 Demographic and clinical variables of the subjects included in the analyses (Continued)
Maternal blood Cord blood
Control group
(n = 26)
Intervention group
(n = 25)
p-value Control group
(n = 68)
Intervention group
(n = 64)
p-value
Monounsaturated fat intake T3 (%kcal) 11.36 ± 2.62 [4] 11.60 ± 2.67 [3] NS 11.39 ± 2.07 [10] 11.33 ± 2.72 [10] NS
Polyunsaturated fat intake T3 (%kcal) 5.52 ± 1.91 [4] 5.93 ± 1.61 [3] NS 5.43 ± 2.07 [10] 5.59 ± 1.63 [10] NS
New-born anthropometry
Gestational age (days) 280 ± 10.00 [1] 284 ± 8.00 0.022 282 ± 12.25 284 ± 10.00 0.048
Child sex - female 17 (65%) 11 (44%) NS 39 (57%) 30 (47%) NS
Birth weight (g) 3860 ± 460.00 4090 ± 480.00 NS 3995 ± 532.50 4105 ± 550.00 NS
Birth length (cm) 52.00 ± 3.00 [6] 52.75 ± 1.88 [7] NS 52.50 ± 2.75 [13] 53.00 ± 3.00 [15] NS
Birth ponderal index (100 g/cm3) 2.60 ± 0.28 [6] 2.81 ± 0.50 [7] NS 2.73 ± 0.44 [13] 2.70 ± 0.41 [15] NS
Values are reported in absolute number (%) or median ± interquartile range. Numbers in square brackets indicate the amount of missing values. P-values were
calculated via Mann-Whitney U-tests and chi-square tests. Abbreviations: GI glycaemic index, T1/T2/T3 (Pregnancy) Trimester 1/2/3, NS non significant
Fig. 1 Manhattan plot for the association of maternal metabolites with the RCT arm. Associations were calculated via generalized additive model
with correction for maternal BMI, baseline metabolite levels, sample storage time (non-linear effect) and random intercept for batch number. The
full list of legend abbreviations is available in the methods section
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(though non-significant after correction for multiple
testing), while cord blood metabolome was not substan-
tially affected by the intervention.
Maternal blood
All changes identified in maternal blood between control
and intervention groups were related to fatty acids (FA),
either non-esterified or in the form of acyl esters or PL
chains. PLs are membranes lipids whose abundance is
associated with both endogenous metabolism and diet-
ary intake [14, 22]. The amount and composition of diet-
ary fat consumed by the mothers did not change over
pregnancy or due to the intervention, thus an exogenous
change in fat intake can be excluded. It is possible that
the low-GI diet modifies metabolism towards the release
of fat from adipose tissue, hence the usage of fat as
source of energy (as seen in the higher FAO markers
and AC) and their transport (via PL).
A recent study by Hernandez-Alonso et al. found that
a low-GI diet over 6 months was associated with changes
in amino acid concentrations (both positively and nega-
tively) and with a marked decrease in phospholipids,
particularly SM and LPC, when compared both intra-
subject to the patient’s own baseline levels or inter-
subjects against patients following high GI or low fat
diets [17]. In our results, subjects in the intervention
group showed no differences regarding AA, but higher
levels of phospholipids, especially those containing FA
with 16 and 18 carbon atoms chains, than subjects in
the control group. To evaluate these discrepancies, it
should be noted that the populations and study design
largely differed: Hernandez-Alonso et al. investigated
overweight and obese men and women in a calories-re-
stricted setting for over 6 months, while our population
was composed of pregnant women in the second half of
gestation who embraced an isocaloric, low-GI diet for
12 weeks. In particular, a 6 months calories-restricted
diet can be seen as a prolonged catabolic state, while in
pregnancy a first anabolic state spanning until the end of
the first trimesters is followed by an accelerated
catabolic state in the third trimester [19, 20, 29];
Table 2 Results from maternal blood analysis. Since no metabolite
was significant after Bonferroni correction, only results with
uncorrected p < 0.05 are presented here (for complete results,
including Bonferroni correction: see Additional file 2). Beta > 0
indicates higher values of the analyte in the intervention group
Analyte Analyte group Beta (Std.) 95% CI (Std.) p-value
16:1 NEFA 0.61 (0.09, 1.12) 0.027
18:1 NEFA 0.62 (0.07, 1.17) 0.032
AC C8:0 Acylcarnitines 0.58 (0.05, 1.11) 0.037
AC C8:0:OH Acylcarnitines 0.59 (0.09, 1.1) 0.028
AC C10:0 Acylcarnitines 0.6 (0.06, 1.14) 0.035
AC C12:1 Acylcarnitines 0.57 (0.03, 1.11) 0.045
AC C14:1 Acylcarnitines 0.87 (0.38, 1.37) 0.001
AC C14:2 Acylcarnitines 0.73 (0.21, 1.25) 0.008
AC C16:2 Acylcarnitines 0.51 (0.03, 1) 0.046
AC C18:1 Acylcarnitines 0.57 (0.02, 1.12) 0.049
LPC a C16:0 LPC 0.52 (0.05, 0.98) 0.037
LPC a C18:1 LPC 0.62 (0.11, 1.13) 0.022
LPC e C18:0 LPC 0.65 (0.22, 1.07) 0.005
PC aa C28:1 PC aa 0.48 (0.05, 0.92) 0.035
PC aa C36:0 PC aa 0.64 (0.19, 1.09) 0.008
PC aa C38:0 PC aa 0.54 (0.07, 1.02) 0.03
PC aa C38:1 PC aa 0.65 (0.17, 1.13) 0.012
PC aa C40:1 PC aa 0.55 (0.13, 0.97) 0.015
PC ae C28:2 PC ae 0.58 (0.15, 1.01) 0.011
PC ae C30:1 PC ae 0.53 (0.03, 1.02) 0.043
PC ae C32:2 PC ae 0.77 (0.37, 1.16) 5.21e-04
PC ae C36:0 PC ae 0.63 (0.16, 1.1) 0.012
PC ae C36:1 PC ae 0.54 (0.05, 1.04) 0.037
PC ae C36:2 PC ae 0.73 (0.2, 1.26) 0.01
PC ae C40:0 PC ae 0.53 (0.03, 1.03) 0.044
PC ae C40:1 PC ae 0.55 (0.05, 1.05) 0.037
PC ae C40:2 PC ae 0.51 (0.13, 0.88) 0.011
PC ae C42:1 PC ae 0.47 (0.08, 0.86) 0.023
SM C34:2 SM 0.53 (0.03, 1.03) 0.044
SM C35:1 SM 0.58 (0.08, 1.07) 0.027
SM C35:2 SM 0.61 (0.15, 1.06) 0.014
SM C37:1 SM 0.61 (0.09, 1.13) 0.027
SM C39:2 SM 0.59 (0.15, 1.02) 0.012
SM C41:2 SM 0.58 (0.14, 1.03) 0.015
SM C42:1 SM 0.52 (0.06, 0.98) 0.032
SM C42:2 SM 0.71 (0.22, 1.19) 0.007
SM C42:3 SM 0.62 (0.16, 1.07) 0.011
SM C43:1 SM 0.74 (0.23, 1.24) 0.006
SM C43:2 SM 0.84 (0.38, 1.29) 7.94e-04
SM C43:3 SM 0.68 (0.23, 1.14) 0.006
Sum SM Sums and Ratios 0.55 (0.05, 1.06) 0.038
Table 2 Results from maternal blood analysis. Since no metabolite
was significant after Bonferroni correction, only results with
uncorrected p < 0.05 are presented here (for complete results,
including Bonferroni correction: see Additional file 2). Beta > 0
indicates higher values of the analyte in the intervention group
(Continued)
Analyte Analyte group Beta (Std.) 95% CI (Std.) p-value
FAO 16:0 Sums and Ratios 0.52 (0.02, 1.02) 0.046
FAO 18:1 Sums and Ratios 0.62 (0.11, 1.12) 0.02
Abbreviations: CI Confidence interval, Std. Standardized estimate,
NEFA Non-esterified fatty acid, AC Acylcarnitine, LPC a Lysophosphatidylcholine with
acyl bond, PC aa diacyl-phosphatidylcholine, PC ae acyl-alkyl-phosphatidylcholine,
SM Sphingomyelin, FAO Fatty acid oxidation
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therefore, our data, collected at the end of the second
trimester, might represent the peak of the anabolic phase
or the begin of the catabolic phase.
All AA modulated by low-GI diet in Hernandez-Alon-
so’s study have been observed to decrease during gesta-
tion [29]; this progression has been linked to the
increased placental uptake for foetal protein synthesis
[29] and it is possible that the foetal needs might domin-
ate over their regulation due to low-GI diet. Maternal
phospholipids, especially PL and SM, have been ob-
served to rise during pregnancy [29, 41]; this rise has
been attributed to oestrogens [42] and similar differ-
ences in phospholipids have also been observed in young
adult women taking hormonal contraceptives [38].
Moreover, a systematic review conducted by Goff et al.
in 2013 found that low-GI diet reduces total and LDL
cholesterol but does not affect HDL cholesterol [13]
(meta-analysis estimate for reduction in LDL for a low-
GI diet of 9–20 weeks from a total population of 1281
study subjects: − 0.16 mmol/l, 95% CI: − 0.24 to − 0.08).
These results refer to intra-subject differences pre- and
post-intervention. In our data, neither the absolute LDL
concentrations at 28th week nor their difference to the
baseline levels were different between the groups.
During pregnancy, a marked increase in circulating lipo-
proteins occurs (e.g., LDL cholesterol is expected to in-
crease from < 2.59 mmol/l in non-pregnant population
to up to 5.8 mmol/l at the end of gestation) [1], as the
high foetal demand for cholesterol is matched solely by
maternal supply during the first two trimesters [18]. It is
plausible that, also in the case of phospholipids, the
cholesterol- and phospholipids-lowering effect of a low-
GI diet might be inhibited by the major endocrinologic
changes enacted to provide for the increased needs of
mother and foetus.
Nevertheless, some of the species higher in the inter-
vention group (total SM, SM C42:2 and C42:3) were
found to be associated with LDL lipoproteins in preg-
nant women in a recent publication by Rauschert et al.
[36]. Moreover, the absolute differences in GI in the
population under investigation were very modest (see
Table 2), so it is possible that a more intensive dietary
intervention beginning pre-conceptually might in fact be
beneficial for prospective mothers with potential lipid
dysregulations.
As for how such changes are enacted, an interesting
study in mice by Stavrovskaya et al. [40] found that GI
and fat composition work synergistically in affecting the
FA composition of cardiolipins, a subclass of mitochon-
drial PLs; that is, the changes in the FA composition of
cardiolipids were more pronounced if the diet was high
GI and high in trans or saturated fat than if either com-
ponent was present alone. In our data, we could not test
this hypothesis due to lack of variability in the dietary fat
intake. Nevertheless, our results, combined with the
findings from Stavrovskaya et al., urge further investiga-
tion of the mechanisms linking fat intake and GI to
lipids composition and fat metabolism.
Cord blood
Cord blood metabolome was largely unimpacted by the
intervention. We did find a small difference in the concen-
tration of Val between the RCT groups in the analysis of
the overlapping subjects which might be indeed be ultim-
ately linked to the lower maternal GI intake (BCAA levels
correlate with and might cause insulin resistance [31],
while a low GI diet should prevent it); however, since the
finding was not replicated in the larger cohort and no
other BCAA was different between the study groups, this
result has to be interpreted carefully.
Fig. 2 Manhattan plot for the association of cord metabolites with the RCT arm. Associations were calculated via generalized additive model with
correction for maternal BMI, gestational age, foetal sex, sample storage time (non-linear effect) and random intercept for batch number. The full
list of legend abbreviations is available in the methods section
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In general, data about the impact of lifestyle interven-
tions on cord blood metabolome are scarce; however, our
results from the ROLO cohort are in line with previous
findings from the UPBEAT study [35], where a lifestyle
intervention in pregnant women with obesity, while
beneficial to the mothers, did not affect cord blood metab-
olome [34]. In particular, the enhanced availability of ma-
ternal lipids was not mirrored in higher transport to the
foetus. This is not surprising, since placental FA transport
is subject to complex regulatory mechanisms [5, 11, 39].
Nevertheless, there is the need of a deeper understanding
of how maternal diet may influence placental transport, as
the data to this regard are scarce [43].
Despite the ROLO trial found no effect of the inter-
vention on birth and early infancy anthropometry mea-
sures [46], epidemiological studies show that the effects
of in-utero exposures on metabolic health might become
evident later in life [24, 26], e.g. because modulated via
epigenetic changes [8, 28]. “Subtle but widespread”
changes in the DNA methylation were found in the cord
blood of babies from the ROLO study, as reported by
Geraghty et al. [9]. In other words, the intervention
might have not impacted foetal metabolism and early
infancy anthropometry, but the in-utero exposure to a
low-GI diet might still show its beneficial effects in later
stages in life.
Strengths and limitations
The strengths of our analysis were the large panel of me-
tabolites (268 analytes, sums and ratios) studied with the
same LC-MS/MS targeted approach, the availability of
data from both maternal and cord samples, and the ex-
tensive dietary data. A major limitation of our study was
the small sample sizes, which nevertheless did not pre-
vent from inspecting the trends in maternal and cord
blood. The small magnitude of the difference in GI be-
tween the study group and the lack of hormonal mea-
surements as confounding factors might also have
obscured additional differences and associations from
being identified.
Conclusions
Our analysis showed that a low-GI dietary interven-
tion in pregnancy was associated with modest but
consistent increases in maternal plasma phospholipids
and utilization of fat as source of fuel, while cord blood
was not affected by this intervention. Our study was the
first to investigate the effect of a low-GI diet in a pregnant
population. Our results were partially in agreement with
studies conducted on non-pregnant subjects, and we
ascribe discrepancies in the findings to the pregnancy-spe-
cific metabolic adaptations enacted to ensure sufficient
nutrients to the developing foetus, for which more re-
search is needed. Our exploratory findings may be used to
direct further investigations about low-GI diets before and
during pregnancy, to improve patient care for pre-concep-
tional and pregnant women with lipid dysregulations and
potentially modulate the offspring’s risk for future onset of
metabolic diseases.
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